<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682314</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201015</org_study_id>
    <nct_id>NCT04682314</nct_id>
  </id_info>
  <brief_title>B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>B-REC</acronym>
  <official_title>B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative&#xD;
      treatment for a variety of hematological malignancies. However, patients who have received&#xD;
      this treatment have a persistent deficit in humoral immunity up to one year post-transplant.&#xD;
      To date, the design of new therapeutic strategies to improve immune recovery in allo-HSCT&#xD;
      patients is still hampered by the fact that post-transplant regenerative hematopoiesis has&#xD;
      never been studied, and more generally by our currently limited knowledge on the development&#xD;
      and function of human B lymphocytes. The main objective of our study is to study early B-cell&#xD;
      progenitor reconstitution after allogeneic hematopoietic stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>B cells reconstitution</measure>
    <time_frame>at day 100 days post-transplant</time_frame>
    <description>B cell clusters as assess by CyTOF technology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>B cells reconstitution</measure>
    <time_frame>at 6 months post-transplant</time_frame>
    <description>B cell clusters as assess by CyTOF technology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perturbations in growth or differentiation of progenitor/precursor of B cells</measure>
    <time_frame>at 100 days post transplant</time_frame>
    <description>Perturbations in growth or differentiation of progenitor/precursor of B cells will be assessed by cytometry technology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perturbations in growth or differentiation of progenitor/precursor of B cells</measure>
    <time_frame>at 6 months post-transplant</time_frame>
    <description>Perturbations in growth or differentiation of progenitor/precursor of B cells will be assessed by cytometry technology</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hematologic Malignancy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18 years and older with hematological malignancies and subject to allogeneic&#xD;
        HSCT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients :&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  with hematological malignancies and subject to allogeneic HSCT&#xD;
&#xD;
          -  with health insurance coverage (bénéficiaire ou ayant droit)&#xD;
&#xD;
          -  having signed a written informed consent.&#xD;
&#xD;
        Inclusion criteria of donor&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  with health insurance coverage (bénéficiaire ou ayant droit)&#xD;
&#xD;
          -  having signed a specific written informed consent.&#xD;
&#xD;
        Exclusion criteria of recipient and donor&#xD;
&#xD;
          -  Absence of written informed consent&#xD;
&#xD;
          -  Patient or donor on AME&#xD;
&#xD;
          -  Patient or donor on AME or under protection by law, tutorship or curatorship&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Gérard SOCIE</last_name>
    <phone>01-42-49-98-24</phone>
    <email>gerard.socie@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu Resche-Rigon</last_name>
    <phone>+33142499742</phone>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

